Organisation paid for research Program year 2025 Source: CMS Open Payments

Brigham & Womens Physicians Organization

Neither a doctor nor a teaching hospital

Research payments

$68,955

24 payments

Through program year 2025, Brigham & Womens Physicians Organization is reported as receiving $68,955 in research payments, across 24 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $32,983 1
2024 Research $3,328 5
2023 Research $17,033 9
2022 Research $15,611 9

Breakdown

Who paid Research payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $32,983 1 payment
  2. Celgene Corporation $21,242 4 payments
  3. H. Lundbeck A S $7,300 5 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $6,240 10 payments
  5. Bavarian Nordic A/S $1,190 4 payments
Studies the money was for Research payments · program years 2022–2025
  1. a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $32,983 1 payment
  2. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) $13,092 2 payments
  3. Paradighm A Natural History Registry for Patients With Chronic Hypoparathyroidism $6,240 10 payments
  4. Ph III Yellowstone CD OLE (RPC01-3204) - A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn s Disease $4,501 1 payment
  5. Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (RESTORE) $3,800 3 payments
  6. Ph III Yellowstone CD Maintenance (RPC01-3203) - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn s Disease $3,649 1 payment
  7. A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy $3,500 2 payments
  8. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $840 3 payments
  9. Nct05238025 $350 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record